Aviragen Therapeutics
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its innovative delivery platform. The company aims to transform global health by pioneering oral pill vaccines that provide both mucosal and systemic immunity against viral diseases, making immunization easier, more accessible, and effective. Vaxart's mission is to create safe, effective, and accessible vaccines to protect communities worldwide and empower healthier lives.
Industries
Nr. of Employees
medium (51-250)
Aviragen Therapeutics
San Francisco, California, United States, North America
Patents
Method for the synthesis of a hydrazine that can be used in the treatment of the papilloma virus
US-9908858-B2
View DetailsAnhydrous crystalline free base form of 6-{2-[1 -(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole
US-9802926-B2
View Details
Method for the synthesis of a hydrazine that can be used in the treatment of the papilloma virus
US-9908858-B2
View DetailsAnhydrous crystalline free base form of 6-{2-[1 -(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole
US-9802926-B2
View DetailsProducts
Oral pill COVID-19 vaccine candidate
Investigational oral tablet vaccine candidate intended to elicit mucosal and systemic immune responses against SARS‑CoV‑2; evaluated in Phase 1 and Phase 2 studies including a large Phase 2b randomized comparator-controlled trial.
Oral bivalent norovirus vaccine candidate
Bivalent oral tablet vaccine candidate targeting the two norovirus genogroups most associated with human disease; evaluated in adults and seniors and tested for immunogenicity in lactating mothers.
Oral influenza vaccine candidate
Oral tablet vaccine candidate against seasonal influenza strains tested in human challenge models; completed Phase 2 human challenge study demonstrating reductions in infection and clinical disease compared to placebo and active comparator.
Oral RSV vaccine development program
Oral vaccine development program for respiratory syncytial virus using oral delivery platform; preclinical cotton rat challenge studies showed sterilizing immunity with an unmodified F-protein antigen, with ongoing strategy evaluation for modified antigens or licensed antigens via partnerships.
Oral HPV therapeutic vaccine candidate
Oral therapeutic vaccine candidate targeting HPV proteins to stimulate T‑cell responses aimed at treating HPV-associated precancerous lesions; preclinical models showed tumor regression and increased survival.
Oral pill COVID-19 vaccine candidate
Investigational oral tablet vaccine candidate intended to elicit mucosal and systemic immune responses against SARS‑CoV‑2; evaluated in Phase 1 and Phase 2 studies including a large Phase 2b randomized comparator-controlled trial.
Oral bivalent norovirus vaccine candidate
Bivalent oral tablet vaccine candidate targeting the two norovirus genogroups most associated with human disease; evaluated in adults and seniors and tested for immunogenicity in lactating mothers.
Oral influenza vaccine candidate
Oral tablet vaccine candidate against seasonal influenza strains tested in human challenge models; completed Phase 2 human challenge study demonstrating reductions in infection and clinical disease compared to placebo and active comparator.
Oral RSV vaccine development program
Oral vaccine development program for respiratory syncytial virus using oral delivery platform; preclinical cotton rat challenge studies showed sterilizing immunity with an unmodified F-protein antigen, with ongoing strategy evaluation for modified antigens or licensed antigens via partnerships.
Oral HPV therapeutic vaccine candidate
Oral therapeutic vaccine candidate targeting HPV proteins to stimulate T‑cell responses aimed at treating HPV-associated precancerous lesions; preclinical models showed tumor regression and increased survival.
Services
Collaborative research, co-development and grant-funded programs with government agencies, philanthropic organizations and industry partners to advance oral vaccine candidates through preclinical and clinical stages.
Collaborative research, co-development and grant-funded programs with government agencies, philanthropic organizations and industry partners to advance oral vaccine candidates through preclinical and clinical stages.
Expertise Areas
- Oral vaccine development
- Mucosal immunology
- Clinical trial design and management
- Human viral challenge studies
Key Technologies
- Oral tablet vaccine delivery
- Adenoviral vector vaccines
- Mucosal IgA assays
- T‑cell immunogenicity assays
News & Updates
Vaxart’s founder and CSO provides a video update to stockholders.
Vaxart responds to additional FAQs from retail investors.
Vaxart begins dosing in a large Phase 2b trial for COVID-19 vaccine.
Vaxart’s founder and CSO provides a video update to stockholders.
Vaxart responds to additional FAQs from retail investors.
Vaxart begins dosing in a large Phase 2b trial for COVID-19 vaccine.
Vaxart’s founder and CSO provides a video update to stockholders.
Vaxart responds to additional FAQs from retail investors.
Vaxart begins dosing in a large Phase 2b trial for COVID-19 vaccine.
Vaxart’s founder and CSO provides a video update to stockholders.
Vaxart responds to additional FAQs from retail investors.
Vaxart begins dosing in a large Phase 2b trial for COVID-19 vaccine.